Penicillins Flashcards
β-Lactam Characteristics
- Same MOA: Inhibit cell wall synthesis
- Same MOR: β-lactamase degradation, PBP alteration, decreased penetration
- Bactericidal in a time-dependent manner, except against Enterococcus spp.
- Short elimination half-life of
Penicillins discovery
Penicillin was accidentally discovered by Dr. Alexander Fleming in 1928
First used in 1941 for the treatment of staphylococcal and streptococcal infections (gram +)
penicillin common structure
All penicillins share a β-lactam ring attached to a 5-membered thiazolidine ring
how do penicillins work?
- Interfere with cell wall synthesis by binding to and inhibiting penicillin-binding proteins (PBPs) located in bacterial cell membranes
- Number, type and location of PBPs vary between bacteria; PBPs are only expressed during cell division
- Inhibition of PBPs leads to inhibition of final transpeptidation step of peptidoglycan synthesis (no cross-linking)
- all are bactericidal (except against Enterococcus)
3 mechanisms of penicillin resistance
- Production of β-lactamase enzymes
- Alteration in structure of PBPs leading to decreased binding affinity
- Alteration of outer membrane porin proteins leading to decreased penetration
Production of β-lactamase enzymes
- Most important and most common mechanism
- the enzyme hydrolyzes the β-lactam ring inactivating the antibiotic;
- over 100 β-lactamase enzymes have been identified
- can be overcome by addition of β-lactamase inhibitors
ex. Penicillin-resistant Staphylococcus aureus (and many others)
gram + vs gram - use of β-lactamases
gram + bacteria release β-lactamase into the extracellular area to inhibit β-lactam
while gram - bacteria release β-lactamase into the periplasma space where β-lactam is distroyed
examples of Alteration in structure of PBPs leading to decreased binding affinity as a method of resistance
methicillin-resistant Staphylococcus aureus (MRSA) and penicillin-resistant Streptococcus pneumoniae (PRSP)
β-lactamase inhibitors will not longer increase the effects of the drugs, bc the binding sites on PBP have changed so the drug cannot bind.
Natural Penicillins
First group of penicillins to be discovered and used clinically
Parenteral agents: Aqueous penicillin G (IV), Benzathine penicillin G (IM, long-acting), Procaine penicillin G (IM)
Oral agent: Penicillin VK (only one with high enough bioavailability to be given orally)
Penicillin VK
natural penicillin that can be given orally bc it is better absorbed therefore giving it a higher bioavailability
penicillin G
natural penicillin (the first one given to humans) must be given via IV
Benzathine penicillin G
natural penicillin given via IM, the only long lasting penicillin can be dosed once a week
natural penicillins are given for
- Drugs of choice for:
penicillin-susceptible S. pneumoniae, infections due to other streptococci, Neisseria meningitidis, syphilis**, Clostridium perfringens or tetani, Actinomyces, Bacillus anthracis (anthrax)
- Endocarditis prophylaxis; prevention of rheumatic fever
Penicillinase-Resistant Penicillins
- Developed in response to the emergence of penicillinase-producing Staphylococcus
- Semisynthetic derivatives of natural penicillin - contain an acyl side chain (prevent hydrolization by penicillinase)
Examples include:
Parenteral agents: Nafcillin *, Oxacillin, and Methicillin (not available)
Oral agent: Dicloxacillin
Penicillinase-Resistant Penicillins are used for
methicillin-susceptible S. aureus* (MSSA)
penicillinase is
a specific B-lactamase, that hydrolyzes the B-lactam ring
3 ways to overcome penicillanase produced by MSSA
- penicillinase-resistant penicillins,
- beta-lactamases inhibitors, or
- changing to cephalosporin core [cefazolin]
Carboxypenicillins
Developed to further increase activity against gram-negative aerobes. Lost some gram+ activity in the process
example: Ticarcillin
Nafcillin
penicillinase-resistant penicillin used to treat MSSA
has a higher risk of Interstitial Nephritis than other penicillins
Carboxypenicillins (ticarcillin) have increased potency against
gram - bacteria :
Enterobacter spp.
Pseudomonas aeruginosa*
Ureidopenicillins
Developed in response to the need for agents with even more enhanced activity against gram-negative bacteria
• Semisynthetic derivatives of the amino-penicillins with acyl side chain adaptations
Examples include:
Parenteral agent: Piperacillin (not available)
Oral agents: None
Ureidopenicillins are good to use against
anaerobes (target organism)
Pseudomonas aeruginosa*
Enterobacter sp.
β-Lactamase Inhibitors
Potent inhibitors of many bacterial β-lactamases
Protect penicillins from being hydrolyzed by some β-lactamases by irreversibly binding to catalytic site of β-lactamase enzyme
Very weak to no antibacterial activity
Examples include: Clavulanate, sulbactam, tazobactam, avibactam (used in combo with cephalosporins)
β-Lactamase Inhibitor Combinations
Available only in fixed-dose combinations with specific penicillins